Jupiter Neurosciences Inc. (NASDAQ: JUNS) has started patient enrollment for its Phase 2a RESET clinical trial evaluating JOTROL, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE